thiotepa has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 3 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| de Boo, L | 1 |
| Cimino-Mathews, A | 1 |
| Lubeck, Y | 1 |
| Daletzakis, A | 1 |
| Opdam, M | 1 |
| Sanders, J | 1 |
| Hooijberg, E | 1 |
| van Rossum, A | 1 |
| Loncova, Z | 1 |
| Rieder, D | 1 |
| Trajanoski, Z | 1 |
| Vollebergh, M | 1 |
| Sobral-Leite, M | 1 |
| van de Vijver, K | 1 |
| Broeks, A | 1 |
| van der Wiel, R | 1 |
| van Tinteren, H | 2 |
| Linn, S | 1 |
| Horlings, HM | 1 |
| Kok, M | 1 |
| Vollebergh, MA | 1 |
| Lips, EH | 1 |
| Nederlof, PM | 1 |
| Wessels, LF | 1 |
| Wesseling, J | 1 |
| Vd Vijver, MJ | 1 |
| de Vries, EG | 1 |
| Jonkers, J | 1 |
| Hauptmann, M | 1 |
| Rodenhuis, S | 1 |
| Linn, SC | 1 |
| Wang, X | 1 |
| Ren, J | 1 |
| Zhang, J | 1 |
| Yan, Y | 1 |
| Jiang, N | 1 |
| Yu, J | 1 |
| Di, L | 1 |
| Song, G | 1 |
| Che, L | 1 |
| Jia, J | 1 |
| Zhou, X | 1 |
| Yang, H | 1 |
| Lyerly, HK | 1 |
2 trials available for thiotepa and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Prote | 2020 |
Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).
Topics: Administration, Metronomic; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chem | 2016 |
1 other study available for thiotepa and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Prote | 2014 |